Friday, Jul 12, 2002
Front Page |
Southern States |
Other States |
Advts: Classifieds | Employment | Obituary |
Ranbaxy had earlier announced the filing of an IND application for this molecule in its oral usage form. Worldwide, this will be the second anti-bacterial molecule of Oxazolidinone class of compounds; but is the first going into clinical investigations with an extended spectrum of activity both in solid and injectable form, according to a release.
The development and ultimate availability of oral and IV formulations of Ranbezolid would be of great assistance in the treatment of life threatening hospital infections.
It would allow clinicians to initiate treatment with the IV formulation and after the patient has stabilised, to switch to oral therapy with the same molecule, thus contributing to early discharge from the hospital.
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |
Copyright © 2002, The
Hindu. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of